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Chapter I 
Past, Present, and Future of 
Liver Transplantation 
David H. Van Thiel, MD, Judith S. Gavaler, PhD, 
Ralph E. Tarter, PhD, and Thomas E. Starzl, MD, PhD 
The ultimate therapeutic step in the treatment of hepatic disease is the provision 
of a new liver, with or without removal of the affected native organ. As of this 
writing, nearly 3,000 liver transplants have been performed in the United States 
alone. Probably another 1,000 have been performed in other countries. 
The Past 
Two different approaches to liver transplantation have been utilized. The first 
consists of insertion of an extra liver (auxiliary liver transplantation) at an ec-
topic location. This approach leaves the recipient's diseased liver alone. The 
alternative approach to auxiliary hepatic transplantation is orthotopic liver 
transplantation. With this operation, the diseased liver is removed, creating a 
space into which the allograft is transplanted, with as normal an anatomic re-
construction as possible based upon the specific liver pathology and the prior 
surgical history of the recipient. 
Auxiliary Liver Transplantation 
The first attempts at whole liver grafting were auxiliary grafts and were carried 
out by Welch et al (l,2). The use of auxiliary grafts for the treatment of benign 
hepatic disease had an initial attractiveness because it was thought that the 
sacrifice of the remaining function of the failing liver could be avoided and 
would provide some reserve in the event of poor performance on the part of 
the liver graft. Unfortunately, the results obtained with auxiliary liver trans-
plantation have been consistently inferior to those obtained with orthotopic liver 
replacement. 
For an auxiliary graft, the arterial supply is derived from either the aorta or 
the iliac artery, whereas venous inflow is provided by either the distal iliac vein 
or the inferior vena cava to the graft's portal vein. The hepatic venous outflow 
is into either the proximal iliac vein or the inferior vena cava. Initially auxiliary 
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grafts produce bile, but after several days they gradually cease to function and 
undergo progressive atrophy. Essentially all attempts at transplanting an extra 
liver (auxiliary transplantation) without removal of the diseased native organ 
have been disappointing (3). As a result, it is generally believed that auxiliary 
transplantation, if used at all, should be reserved for patients with acute hepatic 
disease for whom the objective is temporary life support, during which time 
recovery of the native liver may occur. In such cases, the extra liver is being 
used as a temporary support organ and can be removed once the recipient's 
native liver begins to function. Auxiliary liver transplantation might also be 
considered for those few patients who have had extensive prior abdominal sur· 
gery in the right upper quadrant and for whom orthotopic liver transplantation 
would otherwise be either very difficult or impossible to accomplish. 
The major drawback of auxiliary grafts is that they atrophy and fail to func-
tion with time. That this occurs should not be particularly surprising, however. 
As long ago as 1877, Eck described the procedure of portacaval shunting (4) 
and 16 years later, Hahn et al (5) extended this study by reporting the untoward 
effects of this procedure. These included weight loss, encephalopathy, and liver 
atrophy. It took another 75 years, however, before it was realized that the 
hepatic atrophy produced by portacaval shunting occurs very rapidly, being 
90% complete within 3-4 days. Paradoxically, the mitotic index and the rate of 
thymidine incorporation increase to a level three to four times greater than the 
preoperative level within the liver undergoing atrophy. Subsequently it was 
noted that if the splanchnic venous blood flow is restored to the liver, the liver 
atrophy experienced after portacaval shunting does not occur (6). Based upon 
this observation, it was suggested that portal venous blood might contain one 
or more hepatotrophic factors and that the diversion of these factors away from 
the liver with portacaval shunting is responsible for the hepatic atrophy ex· 
perienced afterward. A contrasting hypothesis, championed by Mann (7), is that 
the hepatic atrophy or lack of atrophy occurring after portacaval shunting is 
blood flow dependent. Several early studies by Child et al (8), using portacaval 
transposition as the experimental model, have been interpreted by some as 
favoring the Mann hypothesis. Specifically, these studies suggest that by re-
placing the diverted splanchnic venous blood with an inflow to the portal vein 
from the inferior vena cava, most of the adverse effects of portacaval shunting 
could be avoided. 
As a result of this observation, the fate of liver tissue given different types 
of portal venous inflow has been investigated. In one such model (9), splanchnic 
venous blood is provided to one segment of the liver via the portal vein, whereas 
the other segments are supplied with blood from the inferior vena cava. The 
segments receiving flow from the vena cava invariably atrophy. Moreover, the 
atrophy cannot be prevented by arterializing the disadvantaged segment. An-
other model, which has been used to evaluate the importance of portal venous 
blood for the maintenance of the hepatic mass, is the so-called double liver. In 
this preparation, blood returning from the pancreas, duodenum, and stomach 
passes to one portion of the liver, while the other half of the liver is perfused 
with venous blood returning from the small intestine. The liver segment perfused 
with blood from the upper abdominal viscera remains normal (10). In contrast, 
the liver perfused with intestinal venous blood undergoes progressive atrophy. 
The role of endogenous insulin as a putative hepatotrophic factor respon-
sible for the maintenance of hepatic volume was suggested when it was found 
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that liver segments atrophy if either a total pancreatectomy is performed or 
alloxan diabetes has been produced (11-13). These same experiments also dem-
onstrated that nonpancreatic substances present in portal venous blood also 
contribute, at least in part, to the hepatotrophic effect of splanchnic venous 
blood, as the atrophy produced in such models is less than that experienced 
with portacaval shunting. These experiments also provide a rational reason for 
the consistently poorer results obtained with liver transplantation using auxil-
iary grafting techniques compared to those obtained with orthotopic grafting 
procedures. 
Orthotopic Transplantation 
Since the beginning of the cyclosporine era, more than 2,000 patients have had 
orthotopic liver transplants. The first such attempts reported were by Cannon 
(14). Subsequently, orthotopic liver transplantation was developed principally 
by Starzl and by Calne (15-17). The technical problems associated with ortho-
topic liver transplantation and the histopathologic features of liver rejection 
were originally studied in dogs (15-18). Using azathioprine and antilymphocyte 
serum (ALS) as the immunosuppressive agents, long-term survival of orthotopic 
liver transplants in dogs was reported by Starzl and others (19-25). 
Subsequently, it was noted that the rejection experienced by orthotopic liver 
homografts in pigs was relatively mild compared with that experienced by livers 
transplanted into dogs (26). This observation provided an important impetus 
for human liver transplantation. 
Orthotopic liver transplantation in a human was first attempted by Starzl 
in 1963 (27). The first extended survival (13 months) was achieved in 1967 
(28,29). Initially, candidacy for this operation was restricted to individuals with 
hepatic malignancy who were less than 55 years old, free of extrahepatic in-
fection, and free of extrahepatic malignancy. This was because transplantation 
for nonneoplastic disease was considered unjustifiable. It became acceptable 
to some only after considerable social and vocational invalidism had occurred 
as a result of hepatic encephalopathy, variceal hemorrhage, hepatorenal syn-
drome, intractable ascites, and a wide variety of other complications of hepatic 
disease (30). As a result, for many years, orthotopic liver transplantation was 
utilized only as a desperate attempt to rescue patients who were obviously dying. 
Unfortunately, deterioration frequently occurred either during evaluation for the 
procedure or during the time it took to identify an appropriate donor organ in 
many early cases. Once initiated, hepatic decompensation in patients with well-
advanced chronic liver disease is rapid and leads to coma, anuria, gastrointes-
tinal bleeding, multiple infections, and, ultimately, death unless liver transplan-
tation can be accomplished. Complicating the course of these early cases further 
was the fact that many of them required ventilatory support and renal dialysis 
both before and after successful liver transplantation. 
With continued experience, it became clear that liver transplantation is 
technically easy for some hepatic diseases and exceptionally difficult for others. 
Whatever the underlying hepatic disease, however, individuals with prior adhe-
sion-forming operations, particularly those in the upper abdomen, have an in-
creased perioperative mortality, especially if the porta hepatis has been dis-
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Table 1.1 Indications for Orthotopic Liver Transplantation 
l. Chronic Advanced Liver Disease 
Predominantly cholestatic diseases 
Primary biliary cirrhosis 
Primary sclerosing cholangitis 
B iJiary atresia 
Familial cholestatic syndromes 
Vascular disease 
Budd-Chiari syndrome 
Predominantly hepatocellular diseases 
Chronic virus-induced liver disease 
Chronic drug-induced liver disease 
Alcoholic liver disease 
Autoimmune liver disease 
II. Hepatic Malignancies That Are Not Otherwise Resectable 
Hepatoma 
Cholangiolar carcinoma 
Unusual nonhepatocellular or bile duct tumors that arise within the hepatic parenchyma 
Isolated hepatic metastases 
Carcinoid 
Pancreatic islet cell tumor 
Others 
III. Fulminant Hepatic Failure 
Viral hepatitis 
A, B, B+, NANB 
EBV, other 
Drug-induced liver disease 
Halothane 
Gold toxicity 
Disulfiram 
Others 
Metabolic liver disease 
Wilson's disease 
Reyes'syndrome 
Organic acidurias 
IV. Metabolic Liver Disease 
Alpha-I-antitrypsin deficiency 
Wilson's disease 
Homozygous type II hyperlipoproteinemia 
Crigler-Najjar syndrome type I 
Protoporphyria 
Some urea cycle deficiencies 
Glycogen storage diseases types I and IV 
Tyrosinemia 
sected for either a portal diversion or a biliary tract reconstructive procedure 
(31). 
The Present 
The principal indications for liver transplantation are shown in Tables 1.1 and 
1.2. The disease indications in pediatric patients (individuals under 18 years of 
age) are different from those in adults. In children, biliary atresia is the leading 
indication; in adults, it is postnecrotic cirrhosis. Other indications in adults 
include primary biliary cirrhosis, sclerosing cholangitis, and a large number of 
metabolic liver diseases. 
A finding in 10% of early operations that often resulted in operative death 
was either a thrombosed or a hypoplastic portal vein. As a result of this ex-
-------_ .. _-... _._---
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Table 1.2 Clinical and Biochemical Indications for Liver 
Transplantation Candidacy 
L Acute Liver Failure 
Bilirubin >20 mgldL 
Prothrombin time >30 seconds above control values 
Progressive encephalopathy of at least grade 3 
II. Chronic Liver Disease 
A. Cholestatic liver disease 
Bilirubin> 12.5 mgldL 
Intractable pruritus 
Intractable bone disease 
B. Hepatocellular liver disease 
Albumin <2.5 gldL 
Hepatic encephalopathy 
Protime >5 seconds above control values 
C. Factors common to both types of liver disease 
Hepatorenal syndrome 
Recurrent spontaneous bacterial peritonitis 
Intractable ascites 
Recurrent episodes of biliary sepsis 
Development of a hepatoma 
perience, all potential liver transplant candidates currently are studied with 
ultrasonography to define the status of their portal vein preoperatively. When-
ever the results are either equivocal or consistent with absence of the portal 
vein, either portal venography as part of a superior mesenteric arteriographic 
study or a nuclear magnetic resonance study is obtained to visualize the portal 
vein. This experience relative to the status of the portal vein, as well as others, 
has led us to develop a formal pretransplant evaluation for all liver transplant 
candidates seen at the University of Pittsburgh. 
This evaluation has six goals: 1) confirmation of the specific hepatic disease 
diagnosis; 2) documentation of the severity of the liver disease; 3) measurement 
of the recipient's intellectual and psychiatric status; 4) assessment of abnor-
malities of extrahepatic organ systems that might adversely affect transplan-
tation; 5) determination of whether liver replacement is anatomically possible; 
and finally, 6) assessment of whether procedures or therapies other than trans-
plantation may be possible (31,32). 
Because livers affected by hepatocellular disease are quite small, a donor 
with a smaller liver and therefore of smaller stature-usually 10 kg less than 
the recipient-is usually sought. Because of the combined effects of coagulop-
athy and portal hypertension in such cases, hemostasis is often difficult to obtain 
until the hypertensive portal venous system is decompressed, either through 
the liver graft or via a portal systemic bypass system. Once the new liver is in 
place, however, improved coagulation is to be expected if a well-preserved donor 
liver has been engrafted. 
The transplant procedure may require many units of blood in patients with 
severe portal hypertension. Adhesions present from previous abdominal oper-
ations, other than portal systemic shunts, often create particularly fragile col-
laterals that tend to bleed profusely. If a. surgically created portacaval shunt 
exists, the anastomosis must be taken down to revascularize the graft ade-
quately.ln such cases, the residual portal vein is frequently sclerotic and fragile, 
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and may be difficult to use. When prior portal venous shunting has been ac-
complished with a functioning mesocaval shunt, the shunt must be closed to 
prevent a "steal" syndrome that would otherwise deprive the liver graft of its 
portal venous blood supply. In most cases, however, mesocaval shunts prohibit 
transplantation as a result of retrograde portal venous thrombosis. 
Transplantation for hepatitis B-induced liver disease has been and contin-
ues to be a clinical problem. The antigen titer in the few patients who have been 
studied has been reduced only temporarily after the operation, suggesting that 
the excised liver is the principal, but not the sole, reservoir for the virus in the 
body (3). Complete clearing of the virus perioperatively has not been achieved 
despite treatment with large quantities of hyperimmune globulin given intra-
operatively in the immediate postoperative period, as well as 1 month after 
transplantation. A course of preoperative immunization with hepatitis B surface 
antigen (HB,.A.g) vaccine to stimulate an antibody response before transplan-
tation and subsequent immunosuppression have failed to result in either viral 
clearance or antibody production in HB,.A.g-positive patients who have been 
transplanted. 
These observations highlight the fact that the risks to medical personnel as 
a result of hepatitis B virus (HBV), non-A, non-B hepatitis (NANB) and human 
immunodeficiency virus (HIV) infections in recipients and donors are substan-
tial. A program to immunize prospectively all staff involved in organ transplan-
tation and to treat staff members after overt exposure with hyperimmune glob-
ulin should be mandatory in all transplant programs. 
Specific Current Indications for Liver Transplantation 
Biliary Atresia 
The prevalence of biliary atresia has been estimated to be between 1 in 7,000 
and 1 in 13,000 live births. With approximately 3.7 million births annually in the 
United States, the number of new cases of biliary atresia per year should be 
between 400 and 500 (34). Most, but not all, of these individuals should be 
candidates for liver transplantation. The exceptions are those who have severe 
associated anomalies of other organ systems that prevent a meaningful life or 
prohibit transplantation for anatomic reasons; such conditions are estimated to 
occur in about 15% of these cases. 
Children with biliary atresia need to be evaluated very carefully, as some 
of them have unexpected intra-abdominal venous and intestinal anomalies that 
prohibit the performance of an otherwise uncomplicated liver transplant (35,36). 
The most serious of these anomalies are an absent inferior vena cava, a pre-
duodenal portal vein, a hypoplastic portal vein, hepatic arteries that are unsuit-
able for arterial reconstruction, and an absent retrohepatic inferior vena cava 
with situs inversus. 
Because of recurrent episodes of cholangitis after a standard porticoenter-
ostomy (Kasai procedure), an increasing number of children with biliary atresia 
have had multiple abdominal operations, particularly diverting jejunostomies. 
These often require later closure because of bleeding or stomal ulceration. The 
net result of such additional surgery has been that liver transplantation becomes 
increasingly difficult because of the highly vascular adhesions that are present 
in the hilar area in such cases. 
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Hepatic Malignancy 
When clinical liver transplantation was originally performed, individuals with 
primary hepatic neoplasms that could not be removed by conventional operative 
procedures were thought to be ideal candidates for liver transplantation. The 
prognosis for all such patients without transplantation was predictable: death 
within 6 months. Moreover, such candidates generally were in good physical 
condition and did not deteriorate while waiting for a donor organ. More im-
portantly, portal hypertension seldom was severe in such cases. Finally, because 
livers filled with tumor are either normal in size or, more usually, enlarged. the 
technical demands of the transplantation procedure in such patients tend to be 
simple in comparison to those in individuals with advanced cirrhosis. 
Unfortunately, the frequency of recurrent tumor after transplantation, as 
well as the recognition that immunosuppression, at least theoretically, accel-
erates metastatic growth, has dampened the initial enthusiasm for this procedure 
for this indication (18,30,35-37). Eighty-five percent of the recipients trans-
planted for this indication who have lived long enough for occult residual tumor 
to be evident have developed metastases. Moreover, recurrent disease is the 
principal cause of death in such recipients. The situation is even worse for those 
with cholangiolar carcinoma. All such recipients have died of recurrent cho-
langiolar carcinoma, usually less than a year after transplantation. 
Categorical exclusion of tumor cases in the future, based upon this less than 
ideal experience with hepatic malignancy, should not be the rule, however. 
Primary hepatocellular carcinomas found incidentally in organs removed for 
cirrhosis have been cured as a result of resection. 
Postnecrotic Cirrhosis 
Individuals with postnecrotic cirrhosis due to viral, autoimmune, or cryptogenic 
mechanisms are candidates for liver transplantation if they have any of the many 
complications that presage death in individuals with advanced liver disease 
(spontaneous bacterial peritonitis, hepatorenal syndrome, recurrent variceal 
bleeding), or if they have recurrent episodes of hepatic encephalopathy or ad-
vanced synthetic dysfunction characterized by hypoalbuminemia and coagu-
lopathy. In general, these cases are difficult because of the combination of in-
tense portal hypertension and coagulopathy. Nonetheless, as a group, they rep-
resent one-third or more of all current adult liver transplant cases. 
Alpha-I-Antitrypsin Deficiency 
The issues of case selection and surgical technique for this metabolic liver 
disease are the same as those for postnecrotic cirrhosis, except that care should 
be taken to perform the transplant prior to the development of irreversible lung 
disease. After a successful operation, the protease inhibitor phenotype of the 
recipient converts to that of the donor, and depressed serum alpha-I-anti-
trypsin levels become normal. Whether lung disease will or will not develop in 
such cases following liver transplantation is not known, but this is thought to 
be unlikely. 
-----K-~--
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Other Metabolic Diseases of the Liver 
A metabolic cure following liver transplantation has either been proven or 
presumed in children with types I and IV glycogen storage disease, tyrosinemia, 
and Wilson's disease (38-42). Most, but not all, of the characteristic pertur-
bations of these metabolic disorders are corrected after liver transplantation 
(31,38-42). 
Alcoholic Liver Disease 
Because alcoholics abuse a variety of organs, disease of the lungs and a variety 
of other organs, particularly the brain, is common in this population. Following 
successful transplantation, noncompliance and recidivism can be problems. 
Nevertheless, alcoholics have been transplanted, and some have experienced 
prolonged subsequent periods of sobriety. A reasonable period of alcohol ab-
stinence prior to liver transplantation appears reasonable but is not essential. 
Such a requirement would certainly reduce the alcoholic candidacy list, either 
by producing a patient who is too well to be legitimately considered for trans-
plantation or by documenting the patient's inability to maintain abstinence and 
comply with medical therapies following transplantation. Those few alcoholics 
who would adhere to a rehabilitation program and yet fail to regain adequate 
hepatic function clearly should be offered transplantation. Despite the many 
potential social and political issues relative to the use of liver transplantation 
for alcoholic cirrhosis, this indication can be expected to become a more fre-
quent reason for liver transplantation in the future. 
Primary Biliary Cirrhosis 
Transplantation for primary biliary cirrhosis is technically easier to perform 
than it is for any other hepatic disease. In this disease, the liver is either normal 
in size or enlarged, venous collaterals are not excessive, and occlusion of the 
recipient portal vein and vena cava during the anhepatic phase of the procedure 
is well tolerated. Recurrence of primary biliary cirrhosis after successful trans-
plantation has been described but is not well accepted generally (43,44). The 
identification of this untoward consequence of transplantation may be difficult, 
if not impossible, until more is known about the pathophysiologic mechanisms 
of the primary disease. For the immediate future, primary biliary cirrhosis re-
mains a major indication for liver transplantation. 
Primary Sclerosing Cholangitis 
The indications for liver transplantation for primary sclerosing cholangitis are 
identical to those for primary biliary cirrhosis, except that many of these patients 
have had prior biliary tract surgical procedures, which make the recipient hep-
atectomy technically more difficult. Whether the original disease recurs in the 
allograft liver is currently uncertain. Moreover, the presence of associated in-
flammatory bowel disease (especially ulcerative colitis) may enhance this risk. 
Should quiescent ulcerative colitis be present, the question of whether or not 
elective colectomy should be performed to prevent disease recurrence in the 
allograft, and possibly cancer of the colon, in an individual who will require 
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Table 1.3 Contraindications to Liver Transplantation 
I. Absolute Contraindications 
A. Active sepsis outside the hepatobiliary tree 
B. Metastatic hepatobiliary malignancy 
C. Advanced cardiopulmonary disease 
D. AIDS 
II. Relative Contraindications 
A. Advanced chronic renal disease 
B. Age greater than 60 years 
C. Portal vein thrombosis 
D. Cholangiolar carcinoma 
E. Hypoxemia with intrapulmonary right-to-left shunts 
F. Hepatitis B s antigen (HB.Ag) and hepatitis B e antigen (HBeAg) positivity 
G. Prior portacaval shunting procedure 
H. Prior complex hepatobiliary surgery 
I. HlV positivity without clinical acquired immune deficiency syndrome (AIDS) 
long-term immunosuppression is important. Currently there are no data avail-
able to answer this question. However, the attitude of gastroenterologists and 
surgeons toward these particular issues has become more conservative, as most 
patients experience a lessening of their ulcerative colitis symptoms following 
liver transplantation, presumably as a result of the associated immuno-
suppression. 
Secondary Biliary Cirrhosis 
The initiating event in patients with this disease has usually been incomplete 
biliary tract obstruction resulting from a series of unsuccessful attempts at ear-
lier biliary tract reconstruction following one of several complicated biliary tract 
surgeries. If such patients are accepted as transplant candidates, the technical 
problems experienced by the surgeons during the procedure can be enormous. 
These arise both as a result of the altered anatomy and as a result of the nu-
merous adhesions and the portal hypertension that are present. The biliary 
sepsis present in most such cases also enhances the risk. 
Budd-Chiari Syndrome 
The fact that portal-systemic diversion by decompressing the liver improves 
hepatic function in some cases and avoids transplantation in some patients with 
the Budd-Chiari syndrome should not be forgotten. Thus many patients with the 
Budd-Chiari syndrome referred for transplantation will have had a prior side-
to-side portacaval shunt. In such cases, the shunt has to be taken down at the 
time of transplantation. This can be very difficult and usually requires a portal 
vein graft. 
Contraindications to Liver Transplantation 
The current list of contraindications to liver transplantation is shown in Table 
1.3. Although only some of these contraindications are absolute, any of them 
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may be very serious. For example, preexisting systemic or local infections create 
highly unfavorable conditions, as do diseases of organs other than the liver, 
such as coexisting severe heart disease or a history of sociopathic behavior such 
as alcoholism or drug abuse. 
Portal-systemic shunts are still being used to control variceal bleeding, but 
they are being recommended far less frequently than before, because the results 
of randomized clinical trials with shunts have not demonstrated a statistically 
significant increase in the survival of patients after portacaval shunting com-
pared to the survival of those without this operation. Worse yet, the outcome 
after portacaval shunting is a decrease in mortality due to gastrointestinal hem-
orrhage, which is replaced by a higher death rate due to hepatic failure and/or 
disability due to hepatic encephalopathy. As a consequence, alternative methods 
(such as sclerotherapy and transhepatic embolization of the left gastric vein) 
to control variceal bleeding nonoperatively without changing the preexisting 
portal venous blood flow patterns have achieved increasing acceptance (45-
49). 
In all side-to-side shunts, the blood returning from the splanchnic bed is 
diverted around the liver. In addition, a variable amount of blood from the liver 
passes into the systemic venous circulation as a result of retrograde drainage 
(a steal phenomenon). Mesocaval H-graft procedures are no exception. In ad-
dition, the prostheses used in these procedures are associated with a high rate 
of late thrombosis that often propagates to involve the portal vein (48-49). 
Selective shunts are technically more difficult and demanding than the more 
conventional diverting shunts. Yet, if they can be accomplished, a distal sple-
norenal procedure can effectively decompress esophageal varices while main-
taining hepatopetal portal venous flow. Thus, selective shunts are preferred to 
other techniques if a shunt procedure is necessary before liver transplantation. 
Organ Procurement and Presenration 
In most transplantation centers in the United States, the criterion of brain death 
based on the concept of irreversible brain injury has been accepted. Under these 
conditions and with an ideal cadaveric donor, the interval of normothermic, 
ischemic injury is reduced essentially to zero. Fortunately, public acceptance 
of these conditions of organ removal has been widespread. Advances have also 
been made in the field of multiple organ harvesting. Usually the donor operation 
is done through a complete midline incision from the suprasternal notch to 
the pubis, which includes splitting the sternum. The aorta is dissected for cross-
clamping at a level that will allow intra-aortic infusion of cold fluids to pass into 
all of the organs to be harvested. When the liver is one of the organs to be 
removed, dissection of the liver hilum begins only after the liver has been infused 
with cold fluid through both the aorta and the portal vein. This technique re-
quires a stable cardiovascular situation (50,51). 
An alternative procedure, which can be done more swiftly in unstable donors 
or those experiencing cardiac arrest, is the "fast method." With this method, a 
clamp is placed on the aorta near the diaphragm and cold solutions are infused 
rapidly, entering the liver both through the normal celiac axis route and through 
the portal vein after passing through the splanchnic viscera. 
In removing a liver for transplantation, there are two essential steps. The 
h 
e 
e 
o 
In 
:0 
s-
to 
Je 
~d 
"e-
)rs 
,a 
ed 
:gh 
'he 
PAST, PRESENT, AND FlJI1JRE 11 
first is to incise the restraining ligaments that bind the organ to the diaphragm 
and body wall. The second is to skeletonize the vessels and bile duct that are 
to be anastomosed to the companion structures in the recipient. 
Donor cardiovascular instability, a need for excessive vasopressor support, 
an excessive period (several days) between initial injury and the pronouncement 
of brain death, or deterioration of renal function suggest poor perfusion of the 
donor kidneys and liver and make the donor organs less than ideal as allografts 
(52-55). The most common explanations for poor graft function, however, are 
inadequate preservation or preexisting hepatic disease. Intelligent screening of 
all prospective donors and the elimination of those whose physiologic situation 
jeopardizes organ function are crucial to the maintenance of a transplant 
program. 
Assuming that donor selection is appropriate, the surgical removal of a good 
donor organ for transplantation depends upon 1) performing a technically per-
fect operation, including recognition of any of the numerous anomalies of the 
hepatic arterial supply; 2) avoiding warm ischemia; and 3) minimizing cold is-
chemia. The first of these requirements is dependent on the knowledge and skill 
of the surgeon. The second is also surgeon dependent and can be met by avoiding 
occlusion of the blood supply during the dissection. The third calls for careful 
timing of the donor and recipient operations, which often take place across 
great distances. After the donor organ has been recovered, the distal aorta, iliac 
arteries, vena cava, and iliac veins of the donor should be removed and preserved 
in a balanced electrolyte solution for possible use as vascular grafts in the re-
cipient, should they be required (51). 
Tissue Matching and Liver Transplantation 
Waiting for a good match at the A, B, and DR loci of the major histocompatibility 
complex is currently not practical and probably will never be practical for liver 
transplantation because of the precarious medical condition of most liver trans-
plantation recipients prior to surgery. It is of interest that hepatic transplantation 
has been performed by both the 5tarzl group and the Cambridge-King's College 
team despite a positive cytotoxic cross-match (52-57). Hyperacute rejection of 
the grafted liver in such cases has either not been seen or is markedly reduced 
in severity compared to that of renal grafts. In animal models of liver trans-
plantation, in which the recipient has preformed heterospecific cytotoxic hu-
moral antibodies, antibody-initiated rejection of the liver has been reported, but 
it occurs at a much slower rate than it does in the kidney (53-57); similarly, 
the mechanisms responsible for graft destruction in ABO-incompatible liver 
transplants are not well understood, but include graft-versus-host disease as 
well as allograft rejection. The reasons such grafts can be performed without 
hyperacute rejection remain to be explained. 
Recipient Preparation and the Transplant Procedure 
Paracentesis and/or thoracentesis may be required before general anesthesia 
can be contemplated in a liver transplant recipient. Transfusions of blood or 
albumin are often useful for the correction of blood volume or other fluid space 
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abnormalities. If fresh whole blood, fresh frozen plasma, or platelets are given, 
improvement in the preoperative coagulation status of the recipient is usually 
possible. 
A bilateral subcostal incision is used, with an upper midline extension 
through the xiphoid process. If removal of the liver is difficult, the incision can 
be extended into the right seventh intercostal space. This latter incision is re-
quired if the recipient's original liver is small. In such cases, special techniques 
are often required to construct adequate recipient vena caval cuffs for anas-
tomoses with the donor organ (58,59). The suprahepatic and infrahepatic vena 
caval anastomoses are performed first. This is followed by reconstruction of the 
portal vein. At a convenient time, air and the potassium-rich organ preservation 
fluid within the graft must be washed out. Portal blood flow is usually restored 
first. After checking for major anastomotic leaks, the hepatic arterial anasto-
mosis is performed, followed by the biliary reconstruction. 
Portal Venous Bypass and Liver Transplantation 
Usually portal and vena caval occlusion can be tolerated during the 45- to 90-
minute anhepatic phase of the operation, despite major reductions in the cardiac 
output and the obligate" hypotension that follows portal vein and vena cava 
clamping (60). The ease with which these vessels can be ocduded has been 
shown to be dependent upon the degree of collateral circulation that has de-
veloped and that allows venous return to occur despite such large vessel oc-
clusion. If severe hypotension occurs with cross-clamping, a bypass system 
should be used (55,59). 
The fact that most patients do well with portal and inferior vena caval cross-
clamping has created an impression in the minds of some surgeons that this 
practice is entirely safe. When portal cross-clamping is performed without a 
bypass, the intestine becomes progressively more boggy and edematous and 
tends to weep into the peritoneal cavity. Subsequently, the recipient often suffers 
from third space fluid losses, peritoneal contamination with the development 
of subsequent enteric bacterial and fungal infections, and postoperative renal 
dysfunction. The extent to which anyone of these complex physiologic events 
contributes to the high perioperative mortality of liver transplantation patients 
has not been delineated until recently. With the routine use of a heparin-free 
venous bypass system, the transplant operation can be performed under con-
trolled circumstances and the rate of postoperative fungal and bacterial infection 
can be reduced dramatically. As a result, patient survival is increased. The 
veno-venous bypass has changed the technical strategy of liver transplantation 
in several other important ways. In the past, when time was a critical factor 
during the anhepatic phase, it was often impossible to perform meticulous he-
mostasis. When the veno-venous bypass is used, hemostatic techniques can be 
applied so that most, if not all. bleeding can be controlled. Moreover, the use 
of a venous bypass system results in improved intraoperative cardiovascular 
stability, preservation of renal function by avoidance of renal vein hypertension, 
excessive blood loss, trauma to the gastrOintestinal tract, and the creation of 
an operating room ambience compatible with training. 
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Operative Problems 
Inadequate Recipient Artery 
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Hepatic transplant surgeons must be ready to use arterial grafts if the recipient's 
hepatic artery is either too small or too inconveniently located to permit an 
adquate anastomosis. The easiest solution to such problems is to attach the 
homograft's hepatic artery to the recipient's abdominal aorta inferior to the 
origin of the renal arteries. The extra length of the vessel required to reach this 
location can be obtained by using as a graft either the thoracic aorta of the 
donor, in continuity with the celiac axis and by turning the donor aorta 180°, 
or the donor common iliac artery after ligating the hypogastric artery. Fortu-
nately, the external iliac artery is almost always a perfect match with the graft's 
celiac axis. 
Portal Vein Problems 
If portal venous thrombosis, sclerosis, or hypoplasia is present and involves the 
splenic and inferior mesenteric veins, the confluence of these veins must be 
dissected free from the pancreas. A cloaca can be created at this junction to 
which an iliac vein graft can be anastomosed to provide the added length re-
quired to reach the donor's portal vein. Without such grafts, many patients with 
portal vein problems, particularly portal vein thrombosis, die in the operating 
room. 
Biliary Tract Reconstruction 
Most of the technical complications experienced in the early days of liver trans-
plantation were associated with biliary tract reconstruction (61,62). Worse yet, 
these problems were often not recognized until quite late in the postoperative 
course. As a result, they were associated with abscess formation and other forms 
of sepsis that contributed directly to the death of patients. Primarily because 
of its convenience, early in clinical liver transplantation a cholecystoduoden-
ostomy was used as the biliary anastomosis. The prevalence of bacteremia fol-
lowing this type of biliary drainage procedure was considerble. The organisms 
usually recovered were those indigenous to the gastrointestinal tract (61,62). 
This situation with the biliary anastomosis was improved somewhat with the 
use of a defunctionalized jejunal limb (Roux-en-Y) to which the gallbladder was 
anastomosed. However, because of frequent cystic duct obstruction (in more 
than one-third of the recipients with this type of biliary anastomosis), this 
method of biliary drainage frequently required one or more surgical revisions 
and, ultimately, conversion to a choledochojejunostomy. Current practice is to 
create a choledochocholedocho anastomosis unless prior biliary tract surgery 
has been accomplished, in which case a choledochojejunostomy (Roux-en-Y) 
is created. The duct-to-duct anastomosis is performed with interrupted ab-
sorbable sutures, using aT-tube stent whenever possible. The T-limb is brought 
out through a choledochotomy in the recipient's portion of the composite duct. 
In small children and occasionally in adults, the available T -tubes are too large 
for such drainage and an internal stent is required, with the distal tip being 
passed into the duodenum. During the graft procedure, the homograft common 
. ". 
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duct must be cut high so that its distal end is well arterialized from the liver. 
Anatomic studies have shown that the blood supply to the graft's bile duct is 
dependent upon retrograde perfusion from hilar vessels and late intra- and ex-
trahepatic biliary strictures are common if this blood supply is not adequate 
(61,62). 
Other Operative Problems 
Coagulation defects must be anticipated in all cases. The bleeding experienced 
intraoperatively can be aggravated by fibrinolysis, which often begins just before 
the revascularization of the homograft. At times, bleeding can assume crisis 
proportions. This circumstance may represent a unique manifestation of the 
hyperacute rejection process seen in liver transplantation. In such cases, bleed-
ing control starts with suture ligation and cautery. With the new liver in place, 
the portal system can be decompressed through the new organ, with the elim-
ination of portal hypertension as an additional contributing factor in controlling 
the bleeding. Meanwhile, platelets, fresh frozen plasma, and blood constituents 
should be transfused as necessary. The most common early postoperative dif-
ficulties include pulmonary insufficiency, renal failure, and persistent intra-ab-
dominal bleeding. 
Late Postoperative Problems 
Major Problems 
The list of late complications includes peritonitis, with or without bowel in-
farction, bile leaks and/or obstruction pancreatitis, pulmonary emboli, extra-
abdominal infections, and psychosis. The most important factor in recipient 
survival is the ability to control graft rejection. Azathioprine and prednisone 
have been shown to have synergistic effects as immunosuppressant agents when 
given together. This combination was the most commonly used immunosup-
pressive regimen worldwide until recently, when cyclosporine became available 
(63-74). Currently, the combination of cyclosporine and steroids is used most 
frequently. Adjuvants to this combination include antilymphocyte or anti thy-
mocyte globulins (ALG or ATG) and, more recently, monoclonal antithymocyte 
globulin (OKT 3), which are given intravenously with standard immunosuppres-
sive agents during the first few weeks or months after transplantation when 
rejection cannot be controlled by other means. 
Nephrotoxicity is the most serious side effect of cyclosporine use (73,74) . 
Fortunately, the renal dysfunction seen with cyclosporine can be reversed with 
appropriate reduction of the dose. Gum hyperplasia, a fine tremor, regional 
flushing, vague abdominal discomfort, seizures, and the development of breast 
fibroadenomas are other known side effects. Although hepatotoxicity has been 
reported, this untoward effect of cyclosporine has rarely been serious in liver 
transplant recipients and can be controlled by dose reduction when it occurs 
(74). 
The most disturbing consequence of cyclosporine use has been the devel-
opment of an Epstein-Barr virus (EBV)-related lymphoproliferative syndrome 
and lymphoma (75). In contrast, the risk of de novo epithelial malignancies with 
i 
I 
PAST, PRESENT, AND FUTllRE 15 
cyclosporine may be less than that experienced with previously used conven-
tional immunosuppressive regimens and, as yet, no such tumors have been 
reported in cyclosporine-treated patients. With previously used conventional 
immunosuppressive drugs, epithelial tumors accounted for 75% of the new tu-
mors seen (75). 
Cyclosporine is usually started preoperatively with an oral dose of 17.5 mgt 
kg. It is continued daily thereafter, but with reduced intravenous (IV) doses, and 
is given twice a day until oral intake can be resumed. At this time, an oral dose 
of 17.5 mg/kg/day is gradually substituted for the IV dose and is typically divided 
into a twice-daily dosage schedule. Steroids are started on the day of operation. 
For adult patients who leave the operating room in relatively good condition, 
a 5-day burst of prednisolone is given, starting at a dose of 200 mg and declining 
by 40 mg/day until a maintenance dose of 20 mg/day is achieved. 
If the patient is in poor condition, the initial burst of high-dose steroid 
therapy can be omitted and replaced with an infusion of OKT 3. A few patients 
suspected of having cyclosporine nephrotoxicity have been switched tempo-
rarily to azathioprine, with resumption of cyclosporine treatment after improve-
ment in their renal function. With less severe renal impairment, the dosage of 
cyclosporine is simply reduced, without the addition of azathioprine. 
If rejection occurs, the principal response has been to administer inter-
mittent large doses of methylprednisolone IV, or to repeat the original 5-day 
burst of steroids, or to settle at a higher maintenance level of steroids. Most 
recently, OKT3 has been used for 7-10 days in such cases. 
Histopathologically, the first sign of rejection in human recipients is the 
appearance within the liver of lymphoblastoid cells that appear to leave the 
smallest portal vessels throughout the graft and accumulate in the portal tracts 
beneath the endothelial lining of the sinusoids. Due to this cellular infiltration, 
the sinusoids become progressively narrowed and occasionally occluded. As a 
result, blood flow through the liver can decrease, with the development of cen-
trilobular ischemia and occasional necrosis (76-7B). In severe cases this cen-
trilobular necrosis can progress to midzonal necrosis, and biochemical liver 
function rapidly deteriorates. 
Marked centrilobular cholestasis and canalicular cholestasis can also occur. 
A precise pathophysiologic explanation for this cholestasis has not yet been 
established. With chronic rejection, the intralobular bile ducts vanish (77 -7B). 
Fibrosis develops and can progress to a true portal cirrhosis in some cases. A 
characteristic feature of the chronic rejection process is intimal and subintimal 
vascular thickening. Hepatic blood flow is reduced in cases of severe rejection, 
making the ischemic liver graft unusually susceptible to bacterial invasion (79-
Bl). 
Currently, the clinical diagnosis of chronic rejection is restricted to those 
patients whose graft biopsy specimens demonstrate arterial intimal thickening, 
hepatic fibrosis, or bile duct paucity. The morphologic findings of chronic re-
jection are not related directly to the postoperative interval and can be seen 
within the first few postoperative months. The clinical manifestations of chronic 
rejection are similar to those of chronic liver failure due to any cause. In contrast 
to the process of acute hepatic rejection, chronic rejection does not respond 
to increased immunosuppression. 
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Causes of Posttransplantation Mortality 
The greatest mortality experienced after liver transplantation occurs early, usu-
ally within the first few months followi~g the procedure. This is true both with 
liver transplantation under conventional immunosuppression and with cyclo-
sporine-steroid regimens. Detailed analyses of the causes of this early mortality 
have been published. The causes of graft failure include primary graft failure, 
massive operative hemorrhage, vascular thrombosis of one of the reconstituted 
homograft blood vessels, intraoperative cerebral air embolism, the presence of 
unanticipated recipient abnormalities, anatomic situations created by previous 
operations, preexisting disabilities, defective biliary tract reconstructions, and 
excessive immunosuppression (especially with prednisone). 
The dominant pathologic diagnoses in grafts that fail are rejection, biliary 
obstruction, recurrent carcinoma, HBV infection, and recurrent Budd-Chiari syn-
drome which occurs less often (77,78). The time at which changes in current 
postoperative management are most likely to produce a substantial reduction 
in future mortality figures is during the immediate perioperative period. 
The effect of the original disease indication for liver transplantation and the 
technical difficulty of the procedure have not been recognized as being important 
until relatively recently. Clearly, when patients with previous abdominal oper-
ations at or near the hepatic hilum (such as repeated biliary tract reconstruc-
tions anellor portacaval anastomosis) undergo liver transplantation, the pro-
cedure is considerably more difficult. As a result, survival in such cases is 
reduced. In this regard, it is important to remember that surgical procedures 
that jeopardize the candidacy for transplantation should be avoided in patients 
with chronic liver disease. Fortunately, alternative procedures utilizing inter-
ventional radiologic techniques are becoming more widely available. Moreover, 
sclerotherapy for the control of variceal bleeding rather than portal diversion 
is becoming increasingly accepted as a reasonable therapy. 
Retransplantation 
When a transplanted liver fails, aggressive attempts at retransplantation offer 
the only chance for survival. One of the more commonly seen judgment errors 
in liver transplantation is the attempt to gain improvement in hepatic function 
with greater and greater degrees of immunosuppression until the chance for 
retransplantation is lost as a result of sepsis. Retransplantation, when performed 
early, is surprisingly easy to do. The procedure is greatly simplified by retaining 
vascular cuffs from the supra- and infrahepatic venae cavae and from the portal 
vein of the failing graft. Total retransplantation operative time can be as little 
as 3-4 hours. 
Factors That Affect Survival 
Certain risk factors have been examined for their effect on survival. Among the 
more important ones is age. Throughout the entire history of liver transplan-
tation, pediatric recipients have fared better by 10%-25% than have adults. Two 
high-risk diseases have been identified. Specifically, survival with postnecrotic 
cirrhosis and with primary hepatic tumors is less than it is for any other indi-
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cation. With cirrhosis, the principal problems are the numerous surgical diffi-
culties caused by the pathologic process (coagulopathy and portal hyperten-
sion), the poor condition of the cirrhotic patient, and the universa.l return of 
the original B virus-induced disease in HBV carriers. In patients with primary 
hepatic malignancy the early mortality is low, with more than 80% of the re-
cipients alive at 6 months. Unfortunately, a steady decline occurs thereafter as 
a result of recurrent tumor. 
The Future 
The future of liver transplantation is bright. Clearly, as a result of increasing 
experience, concept development and the formation of principles of disease 
development, progression, and therapy are to be expected. Currently, it is gen-
erally held that specific liver diseases require specific therapies. In the future, 
subtypes of various complications of liver disease such as hepatic encepha-
lopathy will require specific and different therapeutic modalities. Crisis man-
agement in the field of liver disease has been and will continue to be replaced 
by carefully thought-out and selected therapies that will be initiated not in re-
sponse to but in an effort to prevent the development of a complication of liver 
disease. 
Such developments should lead to fewer transplants being performed for 
end-stage liver disease and more being performed for selected indications. As 
the clinical arena of liver disease shifts from crisis management to disease con-
trol and the application of specific therapies for specific indications, one or 
more artificial livers, which perform one or more hepatic functions, will be de-
veloped. As a result, liver transplantation for fulminant hepatic failure will be 
utilized less often, but will be applied more often for the problem of subacute 
hepatic failure. 
It should be noted that liver transplantation provides hepatologists not only 
with challenges but also with the tools to address these new challenges. Spe-
cifically, liver transplantation centers will become centers of excellence in he-
patic disease in its broadest sense. As a result, patients with liver disease will 
either seek out or be referred to such centers. Thus the epidemiology and natural 
history of poorly defined and as yet unrecognized liver diseases will be identified 
throughout the entire course of the disease. The removed organs will provide 
tissues, cells, viruses, DNA and other materials, and agents that are responsible 
for or which modify the liver disease. 
Patients with new organs and on immunosuppressive therapy will develop 
old diseases with new faces, as well as totally new diseases. Issues relative to 
the complications, progression, and/or reversal of hepatic disease following liver 
transplantation will be addressed. The important issue of disease recurrence in 
a new organ will be considered. The forces that produce these diseases or modify 
their presentation, when and if they recur, will be identified and studied. The 
information gained will provide new insights into the pathogenesis of individual 
liver diseases and their complications. 
Thus, hepatologists will be challenged to: 
1. develop better definitions of diseases. 
2. identify specific disease mechanisms. 
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3. clarify the pathophysiologic mechanisms of hepatic disease complications 
involving other organs, such as the brain, bone, lungs, kidneys, and endocrine 
systems. 
Concerning the specific issue of disease recurrence, we already know that 
certain diseases, such as the Budd-Chiari syndrome, hepatic cancer, and cho-
langiolar cancer, as well as HBV-positive (DNA + ) disease, recur in the allograft. 
Does NANB hepatic disease recur as well? Do primary biliary cirrhosis and 
primary sclerosing cholangitis recur? Does autoimmune chronic active hepatitis 
recur? To the naive, these questions appear rather simple and easy to answer, 
but to the committed hepatologist and transplant surgeon, they are currently 
very difficult, if not impossible, to answer. The reason for this marked difference 
in perspective is that the latter two types of physicians recognize the problems 
of specific liver disease identification based upon present standards (44). Cur-
rently, only a few liver diseases are diagnosed utilizing the identification of a 
specific agent or enzyme defect and the characteristic histopathology and/or 
clinical course. These diseases can be said to be identified utilizing a "gold 
standard." Many more liver diseases are recognized as a result of a "silver stan-
dard" that involves a characteristic and unique but not pathognomonic pa-
thology, often with characteristic and unique serologic responses. Unfortunately, 
no specific agent or pathophysiologic mechanism of disease has been recognized 
in these cases. Even more discouraging, however, is the fact that many more 
liver diseases are identified utilizing a "copper standard." That is, they have a 
characteristic but not unique pathology, and no characteristic serologic or bio-
chemical markers. Clearly, utilizing anything but a gold standard makes the 
recognition of disease recurrence, as distinct from the development of a new 
disease in a new organ, difficult, if not impossible. 
Additional questions that will be answered as a result of the increasing 
experience with liver transplantation include the following: 
1. Why do liver rejection and chronic active hepatitis differ so markedly his-
topathologically when the mechanisms involved appear to be so similar, and 
dependent upon an active T -cell-dependent immune response? 
2. What is the role of cell surface and intracellular organelle antigens in liver 
disease initiation, progression, perpetuation, and possibly disease 
recurrence? 
It is expected that new and better methods of rejection control and, hope-
fully, prevention (tolerance) will be developed. These will include methods or 
techniques of modulating antigen processing cell (APC cells) and suppressor 
cell numbers, function, and lymphokine modulation/neutralization. 
An alternative to enhanced prevention or control of rejection will be meth-
ods and techniques of initiating, modulating, and selectively regulating hepa-
tocyte and bile duct cell regeneration. Should controlled regeneration be pos-
sible, at a rate that equals the rate of losses due to rejection, a new and entirely 
different state of or concept of "tolerance" will develop. 
The knowledge that evolves from attempts to achieve these aims in the 
clinical arena of liver transplantation will also be applied to the problem of 
fulminant hepatic failure. Growth factors or regeneration modulators will be 
developed and used in patients with this lethal problem. As a result, the number 
of transplanations for fulminant hepatic failure will be reduced, and the number 
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of such patients recovering without the need for transplantation (new suc-
cesses), as well as the number operated on for subacute hepatic failure (per-
sistent therapy failure), will increase. Fortunately, the number of the latter will 
be reduced markedly from the current level. 
Finally, the organs removed at the time of transplantation will provide the 
necessary raw materials for the preparation, characterization, and probable ex 
vivo production of somatomedins and osteocalcins, materials that can be used 
to treat and/or prevent the growth failure and bone disease that currently char-
acterize patients with advanced liver disease. 
Clearly, much has been learned from the past. Much continues to be done. 
And the future is very promising. 
This work was supported by grants NlOOK AM R0132556 and NIAAA ROI06601 , 
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